表紙
市場調査レポート

慢性冠動脈疾患(CAD)(虚血性心疾患) : パイプライン製品の分析

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 321903
出版日 ページ情報 英文 175 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.55円で換算しております。
Back to Top
慢性冠動脈疾患(CAD)(虚血性心疾患) : パイプライン製品の分析 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H2 2015
出版日: 2015年10月21日 ページ情報: 英文 175 Pages
概要

慢性冠動脈疾患(CAD)は、最も一般的な種類の心疾患です。コレステロール等、プラークと呼ばれる物質が心筋に血液を送る冠動脈内壁に堆積し、硬化・狭窄することによって起こります。最も多い症状は狭心症、胸痛であり、その他息切れ、動悸、頻脈、めまい、悪心、発汗などが現れる場合があります。

当レポートでは、慢性冠動脈疾患(CAD)(虚血性心疾患)に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

慢性冠動脈疾患(CAD)(虚血性心疾患)の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

パイプライン製品の概要

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

開発中の製品:企業別

治療薬の開発に従事している企業

  • Gilead Sciences, Inc.
  • Human Stem Cells Institute
  • Juventas Therapeutics, Inc.
  • Lacer, S.A.
  • Nuo Therapeutics, Inc.

治療薬の評価

  • 単独療法の製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • ALD-201
  • Biglycan Therapy for Cardiovascular Diseases
  • Cryocell
  • Gene Therapy to Activate Vascular Endothelial Growth Factor for Cardiovascular Diseases
  • JVS-100
  • LA-419
  • Oligonucleotides for Ischemic Heart Disease and Duchenne Muscular Dystrophy
  • ranolazine ER

最新のパイプライン製品情報

開発休止中のプロジェクト

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC6848IDB

Summary

Global Markets Direct's, 'Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H2 2015', provides an overview of the Coronary Artery Disease (CAD) (Ischemic Heart Disease)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Coronary Artery Disease (CAD) (Ischemic Heart Disease)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Coronary Artery Disease (CAD) (Ischemic Heart Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) Overview
  • Therapeutics Development
    • Pipeline Products for Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Overview
    • Pipeline Products for Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Comparative Analysis
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics under Development by Companies
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics under Investigation by Universities/Institutes
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Products under Development by Companies
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Products under Investigation by Universities/Institutes
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Companies Involved in Therapeutics Development
    • Amarantus Bioscience Holdings, Inc.
    • AnGes MG, Inc.
    • AstraZeneca Plc
    • Bayer AG
    • Biosidus S.A.
    • Biscayne Pharmaceuticals, Inc.
    • Capricor Therapeutics, Inc.
    • Eagle Pharmaceuticals, Inc.
    • Eli Lilly and Company
    • Gilead Sciences, Inc.
    • Hemostemix Ltd
    • Human Stem Cells Institute
    • Juventas Therapeutics, Inc.
    • Lacer, S.A.
    • Lee's Pharmaceutical Holdings Limited
    • Lonestar Heart, Inc.
    • MedImmune, LLC
    • Merck & Co., Inc.
    • Miltenyi Biotec GmbH
    • Multi Gene Vascular Systems Ltd
    • Nuo Therapeutics, Inc.
    • Pluristem Therapeutics Inc.
    • The Medicines Company
    • ViroMed Co., Ltd.
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ACP-01 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALD-201 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AMRS-001 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • anacetrapib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BAY-606583 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • beperminogene perplasmid - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BIS-5409 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bivalirudin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bivalirudin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BQ-123 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • C2 ceramide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • C6 ceramide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cangrelor - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CAP-1002 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cryocell - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • evacetrapib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gemacell - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy to Activate VEGF for Ischemia - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ISIS-APOARx - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • JVS-100 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LA-419 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MEDI-6012 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MultiGeneGraft - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MZ-004 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • neovasculgen - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Oligonucleotides for Ischemic Heart Disease and Duchenne Muscular Dystrophy - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PLX-PAD - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Protein for Cardiovascular Diseases - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Proteins for Ischemic Heart Disease - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ranolazine ER - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rivaroxaban - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Coronary Artery Disease - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Gamma Butyrobetaine for Coronary Heart Disease - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Stem Cell Therapy for Cardiovascular Disease - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptides to Activate CD36 Receptor for Cardiovascular Diseases and Macular Degeneration - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VM-202 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ZK-001 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Recent Pipeline Updates
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Discontinued Products
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Product Development Milestones
    • Featured News & Press Releases
      • Sep 01, 2015: MATRIX Trial Results Presented at Hot Line Session of ESC Congress 2015 and Simultaneously Published in The New England Journal of Medicine
      • Sep 01, 2015: Analysis from CHAMPION PHOENIX Trial Highlight the Efficacy of Cangrelor among Patients undergoing PCI via the Radial Approach
      • Jul 23, 2015: Eagle Pharmaceuticals' RTU Bivalirudin NDA Accepted for Filing
      • Jun 22, 2015: FDA approves new antiplatelet drug used during heart procedure
      • May 20, 2015: Eagle Pharmaceuticals Submits NDA for Ready-to-Use Bivalirudin to FDA
      • Apr 15, 2015: FDA Advisory Committee Recommends Approval of The Medicines Company's Antiplatelet Therapy Cangrelor
      • Mar 30, 2015: The Medicines Company Receives European Commission Approval for Hospital Acute Care Product : KENGREXAL
      • Mar 11, 2015: The Medicines Company Presents new data on Cangrelor at 2015 American College of Cardiology Scientific Sessions in San Diego
      • Jan 07, 2015: Interleukin Announces Collaboration with Isis Pharmaceuticals for Genetic Testing Services
      • Nov 14, 2014: The Medicines Company to Present New Data on Investigational Antiplatelet Agent Cangrelor at 2014 AHA Annual Scientific Sessions in Chicago
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), H2 2015
  • Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Comparative Analysis by Unknown Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2015
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2015
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by AnGes MG, Inc., H2 2015
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by AstraZeneca Plc, H2 2015
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Bayer AG, H2 2015
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Biosidus S.A., H2 2015
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Biscayne Pharmaceuticals, Inc., H2 2015
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Capricor Therapeutics, Inc., H2 2015
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Eagle Pharmaceuticals, Inc., H2 2015
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Eli Lilly and Company, H2 2015
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Gilead Sciences, Inc., H2 2015
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Hemostemix Ltd, H2 2015
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Human Stem Cells Institute, H2 2015
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Juventas Therapeutics, Inc., H2 2015
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Lacer, S.A., H2 2015
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2015
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Lonestar Heart, Inc., H2 2015
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by MedImmune, LLC, H2 2015
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Merck & Co., Inc., H2 2015
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Miltenyi Biotec GmbH, H2 2015
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Multi Gene Vascular Systems Ltd, H2 2015
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Nuo Therapeutics, Inc., H2 2015
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Pluristem Therapeutics Inc., H2 2015
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by The Medicines Company, H2 2015
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by ViroMed Co., Ltd., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics - Recent Pipeline Updates, H2 2015
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects, H2 2015
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects (Contd..1), H2 2015
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects (Contd..2), H2 2015
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), H2 2015
  • Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top